Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

Texas MPN Workshop 2020 | Update on momelotinib for myelofibrosis

Abdulraheem Yacoub • 18 Aug 2020
Texas MPN Workshop 2020
Anemias Myelofibrosis Myeloproliferative Neoplasms Momelotinib Ruxolitinib
MOMENTUM SIMPLIFY-1

Abdulraheem Yacoub, MD, University of Kansas Medical Center, Kansas City, MO, updates us on the clinical use of momelotinib, a JAK1/JAK2 inhibitor in patients with myelofibrosis, including the results of the SIMPLIFY-1 study (NCT01969838), evaluating momelotinib against ruxolitinib in patients with myelofibrosis. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

MPN Channel VJHemOnc banner, with Claire Harrison, Ruben Mesa, Lucia Masarova, Naveen Pemmaraju

More from Abdulraheem Yacoub

Promising advances and remaining challenges in MDS/MPN overlaps
1:33
Promising advances and remaining challenges in MDS/MPN overlaps
Abdulraheem Yacoub • 3 Oct 2026
Exploring JAK inhibitors and evolving therapies for MDS/MPN overlaps
2:31
Exploring JAK inhibitors and evolving therapies for MDS/MPN overlaps
Abdulraheem Yacoub • 3 Oct 2026
Approaching the selection between rusfertide and interferons when treating PV: advice for clinicians
2:53
Approaching the selection between rusfertide and interferons when treating PV: advice for clinicians
Abdulraheem Yacoub • 2 Oct 2026
Current barriers to early intervention in myelofibrosis
1:58
Current barriers to early intervention in myelofibrosis
Abdulraheem Yacoub • 24 Aug 2024

Related Videos

Using symptom assessment tools to improve MPN care
2:02
Using symptom assessment tools to improve MPN care
Ruben Mesa • 2 Oct 2026
Can treatment-free remission become a reality in polycythemia vera?
1:34
Can treatment-free remission become a reality in polycythemia vera?
Ruben Mesa • 2 Oct 2026
When to switch JAK inhibitor therapy in myelofibrosis
1:08
When to switch JAK inhibitor therapy in myelofibrosis
John Mascarenhas • 1 Oct 2026
Long-term spleen response with combination therapy in myelofibrosis: MANIFEST-2
1:36
Long-term spleen response with combination therapy in myelofibrosis: MANIFEST-2
John Mascarenhas • 1 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals